ArticlemLife2025
Phage therapy of perinephric abscess in kidney transplantation recipients caused by drug-resistant
Article in mLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perinephric abscess, a common complication after kidney transplantation, often results from drug-resistant bacterial infections and is notoriously difficult to treat. Phage therapy has emerged as a promising alternative for such resistant infections. Here, we present two cases of perinephric abscesses in kidney transplant recipients (KTRs) treated with phage therapy. Our findings highlight the need for personalized treatment plans and timely intervention with phage therapy to improve patient outcomes. Future research should focus on overcoming barriers like biofilms to make this treatment more effective. Ultimately, phage therapy could lead to better survival rates and improved quality of life for transplant patients facing severe infections. This study is a step forward in the fight against superbugs, offering a potential alternative when antibiotics fail.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.